Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Amber Bio
AddedFeb 17, 2024
UpdatedJun 18, 2026
Amber Bio

Amber Bio

Seed

Amber Bio, a San Francisco-based biotech firm, pioneers gene editing to reach untapped patient groups.

HQ
San Francisco, CA, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Amber Bio, founded in San Francisco, California, is a biotechnology company dedicated to pioneering new gene editing modalities. Their core mission is to develop multi-kilobase edits that can address previously undruggable patient populations, thereby rewriting the rules of medicine. Amber Bio focuses on creating safe, generalizable, and precise genetic medicine solutions to tackle complex genetic disorders.

The company has attracted notable investors and industry experts who believe in its groundbreaking approach to gene editing. Amber Bio's key achievements include significant advancements in gene editing technology that have the potential to transform treatment paradigms for various genetic diseases. Their innovative work has positioned them as a leading player in the biotech industry, making substantial impacts on both scientific research and patient care.

Amber Bio - Similar Companies

Editas Medicine logo

Editas Medicine

GenEdit logo

GenEdit

genedit.com

Emendo Biotherapeutics logo

Emendo Biotherapeutics

emendobio.com

Acrigen Biosciences logo

Acrigen Biosciences

acrigen.com

Excision BioTherapeutics logo

Excision BioTherapeutics

Airna logo

Airna

airna.com

Epic-Bio logo

Epic-Bio

epic-bio.com

Arbor Biotechnologies logo

Arbor Biotechnologies

arbor.bio

Skylark Bio logo

Skylark Bio

skylarkbio.com

Spotlight Therapeutics logo

Spotlight Therapeutics

spotlighttx.com

Locanabio logo

Locanabio

Ampersand Biomedicines logo

Ampersand Biomedicines

ampersand.bio

GeneTether logo

GeneTether

genetether.com

Amberstone Biosciences logo

Amberstone Biosciences

amberstonebio.com

Caribou Biosciences logo

Caribou Biosciences

cariboubio.com

Amber Bio - Quick Facts

Who are Amber Bio's competitors?

Companies similar to Amber Bio include Editas Medicine, GenEdit, Emendo Biotherapeutics and Acrigen Biosciences.

When was Amber Bio founded?

Amber Bio was founded in 2021.

Where is Amber Bio's headquarters located?

Amber Bio's headquarters is located in San Francisco, CA, US.

When was Amber Bio's last funding round?

Amber Bio's most recent funding round was for $26M (USD) in August 2023.

How much has Amber Bio raised to-date?

As of Aug 3, 2023, Amber Bio has raised a total of $26M (USD).

How many employees does Amber Bio have?

Amber Bio has 2 employees as of Feb 4, 2024.

Amber Bio - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Editing
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified